Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Is ONC getting much closer to a Buy-Out!!
View:
Post by laroplex on Jan 28, 2023 4:52pm

Is ONC getting much closer to a Buy-Out!!

As mentioned before, always a pleasure reading ALL the posts from a few heavy hitters on  here, i agree with our friend Noteable(great research) on buy-out coming soon enough, can't see $ 6-8 Billions though, my guess $1.5 Billion....$25-$30pps(just my opinion).... either way....clock is kicking closer, which BP will it be?.....GLTA
Comment by Noteable on Jan 28, 2023 5:56pm
North of US$ 8 Billion is more in line with an M&A / buyout, for reasons already posted, with some of those independent reasons provided below -  With many companies facing patent and pipeline challenges in the 2024-28 period and the fact that biotech valuations appear to be rebalancing, the sweet spot these days for biotech deals appears to be in the $5 billion to $15 billion range ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities